MedTrace Logo

Evaluation of Metabolic Predictors of Influenza Vaccine Immune Response in the Singapore Elderly Population - the DYNAMIC Trial

NCT03399357 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 240

Last updated 2018-01-16

No results posted yet for this study

Summary

The trial aims to evaluate role of metabolic factors including systemic 25-OH D and diabetes in the adaptive immune response (haemagluttination inhibition titer) to influenza vaccine in the elderly. The influenza vaccine administered in this study will be licensed trivalent inactivated influenza vaccine. Elderly who are age above 65 including those with co-morbidities such as diabetes mellitus will be included. The study has its inclusion and exclusion criteria to determine eligibility for participation.

Conditions

Interventions

BIOLOGICAL

Influenza Vaccine

Inactivated Trivalent Influenza Vaccine (IIV3) 2017 containing: A (H1N1): an A/Michigan/45/2015 (H1N1) - like virus (new strain); A (H3N2): an A/Hong Kong/4801/2014 (H3N2) - like virus; B/Brisbane/60/2008 - like virus

Sponsors & Collaborators

  • Singapore Immunology Network

    collaborator UNKNOWN

  • National Healthcare Group, Singapore

    collaborator OTHER_GOV

  • Tan Tock Seng Hospital

    lead OTHER

Eligibility

Min Age
65 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-05-31
Primary Completion
2018-12-31
Completion
2019-02-28

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03399357 on ClinicalTrials.gov